{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:41:43Z","timestamp":1791160903943,"version":"4.1.0"},"reference-count":24,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2007,11,5]],"date-time":"2007-11-05T00:00:00Z","timestamp":1194220800000},"content-version":"vor","delay-in-days":10749,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[1978,6]]},"abstract":"<jats:sec><jats:title>Summary<\/jats:title><jats:p>In double blind crossover 4 month trials, carbamazepine was compared to phenytoin as sole treatment for 45 patients with uncontrolled partial and generalized epilepsy. EEGs performed at the end of these trials revealed that while using carbamazepine the patients manifested a significant overall increase in diffuse slow waves and an increase in generalized epileptiform discharges without significant accompanying changes in seizure incidence Also, during the carbamazepine trial generalized epileptiform discharges activated by hyperventilation were more frequent in patients with a higher seizure incidence compared to subjects with a lower seizure incidence or patients taking phenytoin. No significant focal EEG changes occurred.<\/jats:p><\/jats:sec><jats:sec><jats:title>R\u00c9UM\u00c9<\/jats:title><jats:p>Lors d'\u00e9tudes crois\u00e9es de quatre mois, men\u00e9es en double aveugle, la carbamaz\u00e9pine a \u00e9t\u00e9 compar\u00e9e a la ph\u00e9nyto\u00efne comme traitement isol\u00e9 chez 45 patients pr\u00e9sentant une \u00e9pilepsie \u00e0 s\u00e9miologie partielle et g\u00e9n\u00e9ralis\u00e9e incontr\u00f41\u00e9e. Des enregistrements EEG effectu\u00e9s \u00e0 la fin de chaque essai ont fait appara\u00eetre que sous carbamaz\u00e9pine, il existait une augmentation significative des ondes lentes diffuses et une augmentation des d\u00e9charges \u00e9pileptiformes g\u00e9n\u00e9ralis\u00e9es tandis qu'il n'y avait pas de modification significative de la survenue des crises. Par ailleurs, durant les traitements par la carbam\u00e0z\u00e9pine les d\u00e9charges \u00e9pileptiformes g\u00e9n\u00e9ralis\u00e9es d\u00e9clench\u00e9es par l'hyperpn\u00e9e \u00e9taient plus fr\u00e9quentes chez les malades ayant le plus de crises par comparaison \u00e1 ceux en pr\u00e9sentant moins ou \u00e0 des patients sous ph\u00e9nyto\u00efne. Aucune modification EEG focale significative n'est survenue.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESUMEN<\/jats:title><jats:p>Durante cuatro meses y en un estudio doble ciego se nan comparado la carbamazepina y la fenitoina como tratamientos unicos en 45 enfermos con epilepsy\u00eda parcial y generalizada no controlada. Los EEGs realizados al final de los estudios mostraron que durante el tratamiento con carbamazepina los paci\u2010entes mostraron un aumento significativo de las ondas lentas generalizadas y un incremento de las descargas epileptiformes generalizadas sin cambios significativos acompa\u00f1antes de la incidencia de ataques. Tambi\u00e9n se observ\u00f3, en el tratamiento con carbamazepina, que las descargas epileptiformes generalizadas activadas por la hiperventilaci\u00f3n fueron mas frecuentes en casos con incidencia m\u00e1s elevada de ataques o en los enfermos tratados con fenitoina. No se observaron alteraciones focales significativas en el EEG.<\/jats:p><\/jats:sec><jats:sec><jats:title>ZUSAMMENFASSUNG<\/jats:title><jats:p>In einer4 Monate dauernden Doppelblind\u2010Crossover\u2010Studie wurde Carbamazepin mit Phenytoin als Mono\u2010therapeutica bei 45 Patienten mit unkontrollierter Partial und generalisierter Epilepsie verglichen. Die EEG\u2010Ableitungen am Ende dieser Versuche zeigten, da\u00df die Patienten unterCarbamazepin eine signifikante Zunahme der diffusen langsamen Wellen und eine Zunahme der generalisierten epileptiformen Entla\u2010dungen ohne signifikante Veranderung der begleitend\u2010en Anfallsh\u00e4ufigkeit aufwiesen. Au\u00dferdem zeigte sich wahrend des Carbamazepin\u2010Versuchs, da\u00df generali\u2010sierte epileptiforme Entladungen, die durch Hyperventilation aktiviert wurden, h\u00e4ufiger bei Patienten auftraten, die eine h\u00f6here Anfallsh\u00e4ufigkeit zeigten verglichen mit solchen, mit niedriger Anfallsh\u00e4ufigkeit oder verglichen mit Patienten, die Phenytoin einnah\u2010men. Es fehlten signifikante fokale EEG\u2010Ver\u00e4nderungen.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1528-1157.1978.tb04491.x","type":"journal-article","created":{"date-parts":[[2007,11,5]],"date-time":"2007-11-05T14:59:31Z","timestamp":1194274771000},"page":"283-291","source":"Crossref","is-referenced-by-count":68,"title":["Carbamazepine and the Electroencephalogram of Epileptics: A Double Blind Study in Comparison to Phenytoin"],"prefix":"10.1111","volume":"19","author":[{"given":"Robert J.","family":"Wilkus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl B.","family":"Dodrill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan S.","family":"Troupin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,11,5]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.112.488.737"},{"key":"e_1_2_1_3_1","first-page":"1875","article-title":"Does tegretol open up new therapeutic possibilities for the treatment of certain neurological and endocrine diseases","volume":"36","author":"Braunhofer J.","year":"1966","journal-title":"Med Welt"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1960.03840120030004"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.24.5.401"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0013-4694(74)90099-6"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.27.11.1023"},{"key":"e_1_2_1_8_1","first-page":"357","article-title":"Indications for Tegretol in the treatment of epilepsy","volume":"117","author":"Haas R.","year":"1967","journal-title":"Wien Med Wochenschr"},{"key":"e_1_2_1_9_1","first-page":"329","article-title":"Long\u2010term treatment of epilepsy with Tegretol","volume":"1","author":"Hanke NFJ","year":"1970","journal-title":"Geneesk Gids"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0013-4694(58)90053-1"},{"key":"e_1_2_1_11_1","first-page":"35","volume-title":"Tegretol in Epilepsy.","author":"Jeavons PM","year":"1972"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1964.tb04348.x"},{"key":"e_1_2_1_13_1","first-page":"1042","article-title":"Clinical experiences with Tegretol\u00ae (G\u201032883), a new antiepileptic with a special influence on epileptic character changes","volume":"93","author":"Lorge M.","year":"1963","journal-title":"Schweiz Med Wochenschr"},{"key":"e_1_2_1_14_1","first-page":"133","article-title":"Carbamazepine: Behavioral, anticonvulsant and EEG effects in chronically hospitalized epileptics","volume":"29","author":"Marjerrison G.","year":"1968","journal-title":"Dis Nerv Svst"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1970.tb03890.x"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1974.tb04028.x"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.11.10.912"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1972.tb05166.x"},{"key":"e_1_2_1_19_1","first-page":"14","volume-title":"The effect of the anticonvulsant carbamazepine on epileptic attacks and on epileptic mental disorders","author":"Shimbo S.","year":"1968"},{"key":"e_1_2_1_20_1","first-page":"293","article-title":"Experiences with G 32883 (Tegretol) in the treatment of epilepsy","volume":"21","author":"Singhal BS","year":"1968","journal-title":"Indian Pract"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1975.tb04761.x"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.27.6.511"},{"key":"e_1_2_1_23_1","first-page":"1","article-title":"The use of Tegretol in Epilepsy","volume":"26","author":"Vigoroux R.","year":"1968","journal-title":"Lyon Med Medit"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1974.tb03993.x"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/91.4.751"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1528-1157.1978.tb04491.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1528-1157.1978.tb04491.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,8]],"date-time":"2023-10-08T01:58:48Z","timestamp":1696730328000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1528-1157.1978.tb04491.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1978,6]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1978,6]]}},"alternative-id":["10.1111\/j.1528-1157.1978.tb04491.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1528-1157.1978.tb04491.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[1978,6]]}}}